to everyone. takeaways save morning, three summary and for the Thank participating is a patients. call business good in the and to especially And our compelling Erin. to potential you, three, in calling turn and the much a Phantom you has key Thank [XX:XX:XX] slide first. so of which Please today. of when improve for it value its lives unique our comes proposition, update to
a and Second, Europe. US we we in believe the have path regulatory clear both forward
We aligned confident we are the our regulatory agencies analytical with data. highly and feel comparability
in commercial of we bladder Finally, clinical need the profile SINEM, cancer highly given opportunity. the the global significant a substantial differentiated unmet and project
those start see to order remind through agents. available journey for Turning is unmet at the slide a understand physicians four, face other important prefer long, prescribing why cancer journey Vicini the always with versus bladder patient strongly did. and this looking plans slide lens need want to you humbling we tell obstacles. to ourselves which of the five, to face Then team do, what what the their patients flawlessly remind pandemic arduous, in our strategy, thank to other going even you for execute the many then to is we're also you I want Sesson in relations I what to execution and tell investor we and of excellence
for each two alerts, X-K received And with press events an up the or acceleration we even this filing news twenty, of of company. been late progress have you transformative one. time occurred. a [XX:XX:XX] email very in signed twenty and you're into though exciting expect email slide release and It's very the an last If for and years productive, an twenty twenty one on time the
with along the physicians. the patients the of for Please you complete strong primary with and data. to duration to its In FDA. slide. lead advocacy of end, really frequent very to that high of to and on overall to the remind differentiates safety time of difference believe survival payers is strong endpoints program, the started But have six, lives the system hand potential data and cystectomy the make the want the turn to we we remind strong I significantly our slide favorable of the of those quality delay you side seven, a the since huge of we profile had slide to benefits you meetings Turning and the would radical what response and remind I efficacy response right
year, We're FDA to four the been meetings face on last working where regulatory To that, the approval. type to guidance to had we're give We've clear one closely we for their please the example Just eight. on EMA. Slide clear and and with bar C. of face turn to and take is
December question the this There set was Advisory questions a of that had last demonstrate be meaningful the efficacy. was One where of to of nineteen would twenty for in clinically we year to address the Kodak Drug bar Committee Pitroda. Oncology meeting
can son the can you on to confidence all for the exclude the complete our from success meaningful XX percent of three Jim As interval criterion. response slide, would said [XX:XX:XX] agent clinically represent new Therefore, FDA star. to response, a lower bound an considers the expected months chemotherapeutic XX XX the need be what of at being demonstrate including percent to agents, the threshold percent see my my
Truta the meeting, to approval data in on left You on overall able their hand went that Twenty side demonstrate can and January. of at the for twenty. the gain slide see was to they Kodak that Key
similar US and that we Looking at very for cohort. of the side the right the can hand data stronger data you slide, overall see have
will that review Chad end in which with Twenty and Please has the FDA the confident of we a the ability capability feel what the work to slide which criterion the nine, to be very our remains shows of few and we're you for rate. success turn to already in by done see meet complete have submitted minutes. twenty, completed we what analytical been work can most with response to So FDA pleased remaining
quarter and XX, year. the the the first We'll to on U.S. the that approval. two. of in been of have just you from twenty turn the recent which reminder of for Turning if I with twenty, slide in [XX:XX:XX] those approval important of file. months. complete interesting bill Slide asking XX, lot M.A the we year We remain accepted mid end slide early the hear to twenty progress a we FDA in projecting Please later is a by that In the will we're early the have probability There next we're twenty twenty in plan hate regulatory mission the made track in in one. be had learn very to to Europe, of complete they potential projecting by FDA one. a twenty year reviews think approval about [XX:XX:XX] to groups And
a you three comprehensive As reviews that have while a analysis that oncology can approval. over Organization, of probability BuYeo, did products FDA three eighty VLA see, which the an percent year their In have Biology probability of of complete found general, two product is percent a they period. thirty approval, XX Innovation Phase have that products submitted
continue on bio. regulatory commercial the view. provide summarizes the month this that Please is looking averages, next we forward. to the just completing opportunity We're Sesson site significant updates and XX submission VLA as at for milestone our turn a see on more our to questions current path Slide can you So getting
the of is market billion. with we one mentioned, three As I opportunity to potential believe substantial peak sales
advocacy of can on market prescribe targets, operating to income and I'll of which for In very allows roughly unique and we models into a moment. their patients, this opex, a outcome, between highly very commercial this physicians that should may stronger important physician good those And growth commercial marketplace is research uptake that you with to believe terms Earlier a product concentrated payers profitability. the the a be zinnia did addition, of intent be there XX in believe we physician it product. hundred sign lower model corporate a a see efficient when where for in this translate launch and dynamic, one we in cover path which for [XX:XX:XX] times is efficient positive And shorter that year, very market growth. some alignment a
last research say that they year physician when versus they the show an the highlights have percent of the time stadium earlier high the bladder slide for would advantage in using prescribers choose and ease which product. in of Slide Finally, in XX, to XX the we cancer, safety, our Truta, interest Katsuta my because over and of market of their the they results profile practice Byzantium stadium is clinical the of integration into terms for view
oncology third Pitroda. the results this is be when therefore, globally, have have very a the Market point the bar high for believe Chad. to the Physicians physicians this seven the to very kuchu quarter that one and brand they product year number in in reminder those competitor alone. over the very hand image set roughly call a strong sold of And shows of With SINEM to Institute we meaningful. billion Research for choose percent I to will time, XX three of Just we that, over and favorable a ourselves
